Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.
Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, Smith DA, Koch KM, Stead AG, Mangum S, Bowen CJ, Spector NL, Hsieh S, Adams VR.
Bence AK, et al. Among authors: doukas ma.
Invest New Drugs. 2005 Jan;23(1):39-49. doi: 10.1023/B:DRUG.0000047104.45929.ea.
Invest New Drugs. 2005.
PMID: 15528979
Clinical Trial.